Neurofibroma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 22: Line 22:
{| class="wikitable"
{| class="wikitable"
|+Differentiating neurofibroma from other diseases
|+Differentiating neurofibroma from other diseases
!Disease entity
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease entity
!Etiology (Genetic or other)
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology (Genetic or other)
!Histopathological findings
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological findings
!Immunohistochemical staining
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Immunohistochemical staining
!Benign/Malignant
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Benign/Malignant
!Risk factors
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
!Common site of involvement
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Common site of involvement
!Clinical manifestations
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
!Other associated features
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Other associated features
|-
|-
|'''Neurofibroma'''
| style="background:#DCDCDC;" align="center" + |'''Neurofibroma'''
|
|
|
|
Line 42: Line 42:
|
|
|-
|-
|'''Schwannoma'''
| style="background:#DCDCDC;" align="center" + |'''Schwannoma'''
|
|
|
|
Line 52: Line 52:
|
|
|-
|-
|'''Palisaded encapsulated neuroma'''
| style="background:#DCDCDC;" align="center" + |'''Palisaded encapsulated neuroma'''
|
|
|
|
Line 62: Line 62:
|
|
|-
|-
|'''Traumatic neuroma'''
| style="background:#DCDCDC;" align="center" + |'''Traumatic neuroma'''
|
|
|
|
Line 72: Line 72:
|
|
|-
|-
|'''Neurotized Melanocytic Nevus'''
| style="background:#DCDCDC;" align="center" + |'''Neurotized Melanocytic Nevus'''
|
|
|
|
Line 82: Line 82:
|
|
|-
|-
|'''Cutaneous Myxoma (Superficial angiomyxoma)'''
| style="background:#DCDCDC;" align="center" + |'''Cutaneous Myxoma (Superficial angiomyxoma)'''
|
|
|
|
Line 92: Line 92:
|
|
|-
|-
|'''Nerve sheath myxoma'''
| style="background:#DCDCDC;" align="center" + |'''Nerve sheath myxoma'''
|
|
|
|
Line 102: Line 102:
|
|
|-
|-
|'''Malignant peripheral nerve sheath tumor'''
| style="background:#DCDCDC;" align="center" + |'''Malignant peripheral nerve sheath tumor'''
|
|
|
|
Line 112: Line 112:
|
|
|-
|-
|'''Dermatofibrosarcoma protuberans (DFSP)'''
| style="background:#DCDCDC;" align="center" + |'''Dermatofibrosarcoma protuberans (DFSP)'''
|
|
|
|
Line 122: Line 122:
|
|
|-
|-
|'''Spindle cell lipoma'''
| style="background:#DCDCDC;" align="center" + |'''Spindle cell lipoma'''
|
|
|
|

Revision as of 18:55, 29 March 2019

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma differential diagnosis

CDC on Neurofibroma differential diagnosis

Neurofibroma differential diagnosis in the news

Blogs on Neurofibroma differential diagnosis

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.

Differential Diagnosis

Neurofibroma must be differentiated from:[1]

  • Schwannoma
  • Dermatofibrosarcoma protuberans (DFSP)
  • Ganglioneuroma
  • Melanocytic nevus
  • Myxoid liposarcoma
  • Solitary circumscribed neuroma (palisaded encapsulated neuroma)
  • Traumatic neuroma
  • Neurotized nevus
  • Superficial angiomyxoma
  • Nerve sheath myxoma
  • Malignant peripheral nerve sheath tumor (MPNST): has marked atypia and increased mitotic activity, may have necrosis
  • Spindle cell lipoma
  • Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
  • Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background
Differentiating neurofibroma from other diseases
Disease entity Etiology (Genetic or other) Histopathological findings Immunohistochemical staining Benign/Malignant Risk factors Common site of involvement Clinical manifestations Other associated features
Neurofibroma
Schwannoma
Palisaded encapsulated neuroma
Traumatic neuroma
Neurotized Melanocytic Nevus
Cutaneous Myxoma (Superficial angiomyxoma)
Nerve sheath myxoma
Malignant peripheral nerve sheath tumor
Dermatofibrosarcoma protuberans (DFSP)
Spindle cell lipoma

References

  1. ↑ Neurofibroma. Libre Pathology 2015. http://librepathology.org/wiki/index.php/Neurofibroma#cite_note-pmid15486243-2 Accessed on November 17, 2015


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Neurofibroma_differential_diagnosis&oldid=1559910"